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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the harmful effects of methylphenidate treatment for children and adolescents with attention deficit hyperactivity disorder
(ADHD) in non-randomised studies.
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B A C K G R O U N D
Description of the condition
Attention deficit hyperactivity disorder (ADHD) is one of the
most commonly diagnosed and treated childhood psychiatric dis-
orders (Scahill 2000). The estimated prevalence in children and
adolescents is between 3% and 5% (Polanczyk 2007), depend-
ing on the classification system used, with boys two to four times
more likely to be diagnosed than girls (Schmidt 2009). Preva-
lence rates have remained stable over the past 30 years and do not
appear to vary between countries (Polanczyk 2014). Individuals
withADHDshowdifficulties in attention and cognitive functions,
for example, problem-solving, planning, orienting, flexibility, re-
sponse inhibition, and working memory (Pasini 2007; Sergeant
2003). Children and adolescents also have high rates of prob-
lems involving affective components such as motivational delay
and mood dysregulation (Castellanos 2006; Nigg 2005; Schmidt
2009).
Many studies have examined environmental risk factors for
ADHD development, however, no specific factor seems to predict
who is and is not at high risk of developing ADHD. At the pop-
ulation level, poverty (families living under the poverty level) is
more likely to be a feature among American children and adoles-
cents diagnosed with ADHD (CDC 2015). In a Swedish cohort
of 811,803 individuals, low family income in early childhood was
highly associated with ADHD (Larsson 2014). Low birth weight
(Indredavik 2004;VanLieshout 2015), prematurity (Bhutta 2002;
Burnett 2014; Elgen 2015), maternal exposure to tobacco (Kovess
2015; Obel 2015), and chemical components like lead (Hong
2015) and manganese (Hong 2014) remain questionable risk fac-
tors for ADHD development.
To be diagnosed with ADHD, a childmust display, before 12 years
of age, excessive inattention, hyperactivity and impulsivity that
impairs his/her functioning or development (APA 2013; WHO
1992). There are 18 symptoms of ADHD according to the prin-
cipal diagnostic classification systems: the International Classifi-
cation of Diseases Tenth Revision (ICD-10; WHO 1992), and
theDiagnostic and Statistical Manual ofMental Disorders (DSM)
Fourth Edition (DSM-IV; APA 1994); Fourth Edition, Text Revi-
sion (DSM-IV-TR; APA 2000); and Fifth Edition (DSM-5; APA
2013).
The DSM-5 and ICD-10 criteria require that the inattention, hy-
peractivity, and impulsivity are pervasive (for example, maladap-
tive symptoms of hyperactivity-impulsivity or inattention that are
present at home and at school, before 6 (ICD-10; WHO 1992) or
12 (DSM-5; APA 2013) years of age, and that persist for at least
6 months. There must also be clear evidence of clinically-signifi-
cant impairment in social, academic, and occupational function-
ing (APA 1994; APA 2000; WHO 1992).
The diagnostic criteria set out in the DSM-IV and DSM-5 di-
vide ADHD into three different subtypes each with their own
particular set of symptoms: ’predominantly inattentive type’, the
’predominantly hyperactive-impulsive type’, and the ’combined
type’ - a combination of both hyperactive-impulsive and inatten-
tive symptoms (APA 2013; Willcut 2012).
Children, adolescents and adults with ADHD are at increased risk
of a broad spectrum of comorbid psychiatric disorders, which fre-
quently result in negative outcomes later in life (Newcorn 2008;
Schmidt 2009). The Multimodal Treatment of Attention Deficit
Hyperactivity Disorder (MTA) trial identified one or more co-
morbid disorders in almost 40% of the participants (MTA 1999).
These included oppositional defiant disorder, conduct disorder,
depression, anxiety, tics, learning disorders, and verbal and cogni-
tive difficulties (Jensen 2001; Kadesjö 2001). More recently, stud-
ies have confirmed such comorbidity (Czamara 2013; Yoshimasu
2012), and noted that excess weight and obesity (Cortese 2016)
are found with ADHD. Depending on the severity, the presence
of these comorbid conditions may modify the medication treat-
ment, adding new classes of medications.
Description of the intervention
Stimulant medications, notably methylphenidate, dexam-
phetamine and atomoxetine (a non-stimulant selective nora-
drenaline reuptake inhibitor), are considered treatments of choice
for children and adolescents with ADHD (Greenhill 2006;
NCCMH 2009b; Pliszka 2007). The decision regarding which
product to use is based upon a range of factors, including types
of comorbid disorders, adverse events associated with the drug,
issues regarding compliance, the potential for drug diversion
and the preference of the child/adolescent and/or parents of the
child. (Note, we use the term ’adverse events’ to describe any
harms, adverse effects or adverse drug reactions associated with
methylphenidate). Very often psychological treatment is recom-
mended as a part of the treatment, or even used before drug treat-
ment (AAP2011; Bolea-Alamañac 2014;NCCMH2009a; Taylor
2004). Globally, methylphenidate is the most commonly used
drug to treat ADHD; it has been used in practice for more than
50 years (Kadesjö 2002; NCCMH 2009b).
Methylphenidate is used because it appears to have a favourable
effect on the major symptoms of hyperactivity, impulsivity, and
inattention in children and adolescents with ADHD. However, a
new Cochrane review investigating the effects of methylphenidate
for children and adolescents with ADHD reported that it was not
possible to demonstrate that methylphenidate offers more benefits
than harms compared to placebo or no treatment (Storebø 2015).
The dose of methylphenidate varies from patient to patient, with
some children responding to relatively low doses and others re-
quiring higher doses. The dose needs to be titrated individually
in order to maximise benefits and minimise any potential adverse
events (Stevenson 1989). It is often titrated according to weight,
with smaller children receiving lower doses. The therapeutic range
of methylphenidate dosages usually varies from 5 mg to 60 mg,
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administered one to three times daily, depending on the release
system and mode of administration (Pliszka 2007; Storebø 2015).
How the intervention might work
It is presumed that the effects of methylphenidate on ADHD
symptoms are related to its effects on dopaminergic and nora-
drenergic neurotransmissions in the central nervous system (CNS)
(Engert 2008). Methylphenidate is thought to act primarily as
a dopamine-norepinephrine reuptake inhibitor, thereby increas-
ing the availability of dopamine and norepinephrine (Heal 2006).
The bioavailability of oral methylphenidate is 11% to 52%,
with an approximate duration of action of 2 to 4 hours for im-
mediate-release methylphenidate, 3 to 8 hours for sustained-re-
lease methylphenidate, and 8 to 12 hours for extended-release
methylphenidate (Kimko 1999). Methylphenidate is believed to
improve function (through symptom control) via dopaminergic
pathways (Barkley 1977; Schulz 2012; Solanto 1998). This may
improve classroom functioning and academic learning (Biederman
2003; Cox 2004; Evans 2001; Swanson 2004; Yang 2004).
Methylphenidate has also been shown to reduce harmful secondary
outcomes. For example, in an extensive cohort of 710,120 indi-
viduals, including 4557 individuals diagnosed with ADHDbefore
10 years of age, the use of methylphenidate was found to reduce
emergency department visits by 45.7% and injuries by 43.5%
(Dalsgaard 2015a).
The mechanism of action of methylphenidate is not clearly un-
derstood, but it probably works by blocking the norepinephrine
and dopamine transporters in the synaptic cleft. This action in-
terrupts neurotransmitter reuptake, increasing dopamine concen-
tration in the cleft (Volkow 1998; Volkow 2004). As a result,
patients can experience several benefits such as improved atten-
tion and reduced hyperactivity-impulsivity (Barkley 1981; Barkley
1989; Connor 2002; Shaw 2012). However, given the lack of
sufficiently powered, well conducted randomised clinical trials
(RCTs), it is not clear if these are genuine benefits or statisti-
cal artefacts (Storebø 2015). In a positron emission tomography
(PET) study with 16 healthy participants, Volkow 2004 demon-
strated that methylphenidate enhanced motivation for cognitive
exercises - following treatment, participants rated the tasks as more
interesting and motivating. In a similar vein, Schweitzer 2004
found that methylphenidate can enhance performance by filter-
ing out distractions in patients with ADHD. Other research has
demonstrated that the accumulation of dopamine after block-
ade by methylphenidate is greater in more inattentive and impul-
sive patients, implying that methylphenidate could benefit those
with more severe symptoms (Rosa-Neto 2005). A recent study
demonstrated that methylphenidate increases dopamine in ven-
tral striatum and prefrontal and temporal cortices, decreasing rates
of inattention (Volkow 2012). In addition, the authors hypothe-
sised that chronic methylphenidate use may result in adaptations
in dopamine striatal signalling.
In a supplementary analysis of the study “A Comparison of
Methylphenidates in an Analog Classroom Setting” (COMACS),
the investigators found that girls responded to methylphenidate
better than boys (Sonuga-Barke 2007; Swanson 2004). Barkley
1991 also found differences in response to methylphenidate be-
tween ADHD inattentive and combined subtypes.
Why it is important to do this review
The most common reported adverse events associated with
methylphenidate are headache, sleep problems, tiredness,
and decreased appetite. Some studies have indicated that
methylphenidate also impairs children’s height and weight (
Schachar 1997; Swanson 2004; Swanson 2009). In addition,
there have been reports of sudden death among adults taking
methylphenidate for the treatment of ADHD, but more re-
search is needed to determine whether these deaths are related to
methylphenidate (U.S. FDA 2011). A recent register-based Dan-
ish study of children and adults with ADHD has shown that chil-
dren with ADHD do have a higher mortality rate compared to
children and adults without ADHD; however, the role of ADHD
medications in this apparent increase in mortality was not inves-
tigated (Dalsgaard 2015b). Because of the limitations of identify-
ing and reporting adverse events in RCTs, particularly with low
prevalence and longer-term effects (Storebø 2015), it is appro-
priate to synthesise data on adverse events from non-randomised
studies. These data can help children and their families, clinicians
and policy-makers make better decisions on the relative risks and
benefits, as well as treatment acceptability, of methylphenidate
(Catalá-López 2013; Donnelly 2004; Hong 2009; King 2006).
Over the last 15 years, several reviews have investigated the effi-
cacy of methylphenidate for ADHD. Most of the reviews have in-
vestigated the effects of methylphenidate on beneficial outcomes,
predominantly with regard to the symptoms of ADHD, and not
potential harms (Storebø 2015). Due to the limitations of ex-
isting reviews, we conducted a comprehensive Cochrane system-
atic review investigating the short-term benefits and harms of
methylphenidate for children and adolescents. We found evidence
to suggest that methylphenidate may have a small beneficial ef-
fect on ADHD symptoms, general behaviour and quality of life
(Storebø 2015). We also found evidence that methylphenidate is
not associated with an increased risk of serious adverse events in
the short term, but is associated with a relatively high risk of non-
serious adverse events in general. However, the quality of the evi-
dence included in the review was very low to low, due to a number
of limitations, including lack of blinding in spite of placebo use,
outcome reporting bias, and heterogeneity. Furthermore, the trials
were generally of short duration, with a mean follow-up of just
over two months, and thus not well suited to detecting rare or in-
sidious adverse reactions, and so there is a need to investigate pos-
sible long-term harms in non-randomised studies (Storebø 2015).
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The advantages of non-randomised studies, compared to RCTs,
in collecting information on adverse events are that they can be
much bigger, allowing for detection of rare adverse events, and
participants can also be followed up for much longer periods,
allowing for detection of late adverse events. On the other hand,
the disadvantage of non-randomised studies compared to RCTs
is the lack of a placebo (or nocebo) comparator, which means
that any apparent association between the intervention and the
observed harmful effect may be related to other factors.
O B J E C T I V E S
To assess the harmful effects of methylphenidate treatment for
children and adolescents with attention deficit hyperactivity dis-
order (ADHD) in non-randomised studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include only the following non-randomised study designs
(Higgins 2011).
1. Cohort studies.
2. Case-control studies.
3. Follow-up periods from RCTs and case studies.
For a description of cohort and case-control studies see Table 1.
Types of participants
Children and adolescents up to and including 18 years of age with
an intellectual quotient (IQ) greater than 70, with ADHD, with
or without comorbid conditions.
We will accept the following diagnoses of ADHD:
1. A diagnosis of ADHD made according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM) Third
Edition (DSM-III; APA 1980), Third Edition Revised (DSM-
III-R; APA 1987), Fourth Edition (DSM-IV; APA 1994), and
Fifth Edition (DSM-5; APA 2013).
2. A diagnosis of hyperkinetic disorders made in accordance
with the International Classification of Diseases (ICD) Ninth
(ICD-9; WHO 1977) and Tenth (ICD-10; WHO 1992)
Revisions.
Types of interventions
Methylphenidate administered at any dosage or formulation as
part of any medical treatment regimen.
Types of outcome measures
Primary outcomes
Number of serious adverse events, defined as any event that leads
to death or is life-threatening, or that requires inpatient hospital-
isation or prolongation of existing hospitalisation, or that results
in persistent or significant disability, or any other important med-
ical event that may jeopardise the patient’s life, or any event that
requires intervention to prevent any of these outcomes.
Secondary outcomes
All other adverse events, including but not confined to the follow-
ing types of events/effects: cardiological, neurological, gastroin-
testinal, sleeping problems, and growth retardation according to
the International Conference on Harmonisation of Technical Re-
quirements for Registration of Pharmaceuticals for Human Use.
ICHHarmonised Tripartite Guideline. Guideline for Good Clin-
ical Practice E6(R1) (ICH 1996).
Adverse events could be measured during treatment, at the end of
treatment, and at the longest follow-up, using rating scales, spon-
taneous reports recorded by the investigators at regular interviews
or visits, and physical examinations or para-clinical examinations.
We will report ’total adverse events’, separated into ’serious’ and
’other”, as defined above, in the ’Summary of findings’ table.
We will also report in this table, up to five additional adverse
events that demonstrate the largest estimated difference between
the methylphenidate group and the control group as well as those
with the highest prevalence.
Search methods for identification of studies
Electronic searches
We will search the following electronic databases to identify rele-
vant studies.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; current issue; part of the Cochrane Library) and
which includes the specialised register of the Cochrane
Developmental, Psychosocial and Learning Problems Group.
2. Ovid MEDLINE (1948 to current).
3. EMBASE (1980 to current; Ovid).
4. PsycINFO (1806 to current; Ovid).
5. CINAHL (Cumulative Index to Nursing & Allied Health
Literature; 1980 to current; EBSCOhost).
6. Conference Proceedings Citation Index - Science (CPCI-S;
1990 to current; Web of Science).
7. Conference Proceedings Citation Index - Social Science &
Humanities (CPCI-S&H; 1990 to current; Web of Science).
8. NDLTD (ndltd.org/resources; all available years).
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9. Clinical Trials.gov (Clinical Trials.gov; all available years).
10. World Health Organisation International Clinical Trials
Registry Platform (WHO ICTRP; who.int/ictrp/en; all available
years).
Since we will include data from follow-up periods from RCTs,
and also from non-randomised studies, we will use two different
search strategies, one for efficacy and one for adverse events of
methylphenidate.We will not limit our searches by language, year
of publication, or type of publication. We will seek translations of
the relevant sections of non-English language articles. The search
strategies for Ovid MEDLINE are in Appendix 1, and will be
adapted for the other sources.
Searching other resources
To find additional relevant trials not identified by electronic
searches, we will check the reference lists of other relevant reviews,
meta-analyses and studies. We will also contact responsible parties
of trials and pharmaceutical companies for data by email. Finally,
we will search for unpublished data on the websites of the United
States Food and Drug Administration (FDA) and the European
Medicines Agency (EMA).
Data collection and analysis
Wewill conduct the review according to theCochraneHandbook for
Systematic Reviews of Interventions and PRISMA (PreferredReport-
ing Items for Systematic reviews and Meta-Analyses) guidelines
(Higgins 2011; Liberati 2009;Moher 2015), and according to the
guidelines in ACochrane RiskOf Bias AssessmentTool: for Non-Ran-
domized Studies of Interventions (ACROBAT-NRSI; Sterne 2014).
We will perform the analysis using the software, Review Manager
(RevMan), Version 5.3 (Review Manager 2014).
Selection of studies
Fourteen review authors (CRMM,ER, FLM,HK,KBR, LA,MH,
MS, NP, OJS, SJH, SR, TB and TDN) will work together in
groups of two and independently screen titles and abstracts of all
records retrieved by the searches; we will resolve uncertainty or
disagreement by consensus. We will obtain the full-text of all po-
tentially relevant reports and assess each against our inclusion cri-
teria. We will discuss disagreements and will consult a third review
author (OJS) if agreement cannot be reached. We will list relevant
non-randomised studies that do not fulfil the inclusion criteria
with reasons for exclusion in the ’Characteristics of excluded stud-
ies’ table.
Data extraction and management
We will develop data extraction forms to facilitate standardisation
of data extraction. We will extract data on participants, study de-
sign and methods, interventions, adverse events, and relevant data
for ’Risk of bias’ assessments.
All review authors will extract data. The authors will work together
in groups of two and each pair will complete the data collection
form independently to ensure accuracy. We will resolve disagree-
ments by discussion or use an arbiter if required. CRMM, FLM,
HK, MH, NP, and OJS will enter the data into RevMan (Review
Manager 2014). In cases where there are not enough data, or where
data in the published trial reports are unclear, we will contact au-
thors requesting them to clarify the missing information.
Assessment of risk of bias in included studies
For each included study, two review authors (LA, SJH,NPorOJS)
will use ACROBAT-NRSI (Sterne 2014), to independently assess
the risk of bias of comparative cohort studies and case-control
studies across the following seven domains.
1. Possible bias due to confounding factors
We will assess risk of bias due to:
• Comorbidity;
• Age;
• Gender;
• Subtypes of ADHD;
• Socioeconomic factors;
• Switch between ADHD medications;
• Adjustment of medication; and
• Any other confounding factor in the study.
2. Possible bias due to selection of participants
We will assess risk of bias due to:
• Inclusion of patients;
• Time from diagnosis to inclusion in study; and
• Naive to methylphenidate versus non-naive patients.
For case-control studies, we will assess risk of bias due to:
• Selection of controls.
3. Possible bias due to measurement of interventions
We will assess risk of bias due to:
• Measurement of intervention status at start of follow-up;
and
• Self reporting of intervention status.
4. Possible bias due to departures from intended
interventions
We will assess risk of bias due to:
• Compliance with assigned medication;
• Practitioner administration;
• Characteristics of the healthcare setting, for instance, public
outpatient versus hospital outpatient;
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• Adverse events; and
• Lack of efficacy of treatment.
5. Possible bias due to missing data
We will assess risk of bias due to:
• Loss to follow-up.
For case-control studies, we will assess risk of bias due to:
• Difference in follow-up between cases and controls.
6. Possible bias in measurement of outcomes
We will assess risk of bias due to:
• Self reporting of adverse events; and
• Error in instruments measuring adverse events.
7. Possible bias in selection of reported results
We will assess risk of bias due to:
• Type of analysis; and
• Selection of results.
Review authors will judge each domain to be at low risk of bias,
moderate risk of bias, serious risk of bias, critical risk of bias, or
no information, as follows.
Low risk of bias
Description: The study is comparable to a well-performed RCT.
Judgement: The study is judged to be at low risk of bias for all
domains.
Moderate risk of bias
Description: The study is sound for a non-randomised study, but
cannot be considered comparable to a well-performed RCT.
Judgement: The study is judged to be at low or moderate risk of
bias for all domains.
Serious risk of bias
Description: The study has some important problems.
Judgement: The study is judged to be at serious risk of bias in at
least one domain, but not at critical risk of bias in any domain.
Critical risk of bias
Description: The study is too problematic to provide any useful
evidence on the effects of the intervention.
Judgement: The study is judged to be at critical risk of bias in at
least one domain.
No information
Description: There is no information on which to base a judgment
about risk of bias.
Judgement: There is no clear indication that the study is at serious
or critical risk of bias and there is lack of information in one or
more key domains of bias.
Review authors will resolve any disagreements by discussion and
will report any discussions on the data extraction forms.
Measures of treatment effect
Dichotomous data
We will summarise dichotomous data as risk ratios (RR) with
95%confidence intervals (CI).Wewill calculate the risk difference
(RD) and the number needed to treat for an additional harmful
outcome (NNTH). We will present pooled prevalence data from
non-comparative studies.
Continuous data
For continuous data, we will calculate the mean difference (MD)
between the two groups and present it with 95% CI. We will use
the overall MD, where possible, to compare outcome measures
from trials. We will estimate the standardised MD (SMD) where
studies use different measures to assess the same outcome. If trials
do not reportmeans and standard deviation (SDs) but report other
values, such as t-tests and P values, we will calculate the SD using
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Dealing with missing data
We will try to obtain missing data by contacting the authors of
the studies. If data remain unavailable, we will try to estimate the
missing data using the available information. (If the SD is missing
we will estimate it from a standard error if reported). We will also
attempt to impute missing SDs for continuous data from another
study that has similar summary statistics. We will evaluate the
methods used to handle themissing data by excluding these studies
in a sensitivity analysis, and we will discuss the extent to which
the missing data are likely to influence the results of the study.
Assessment of heterogeneity
We will assess the following types of heterogeneity: clinical (vari-
ability in participants, interventions or setting); methodological
(variation in study designs); and statistical heterogeneity (varia-
tion in intervention effects). Heterogeneity between studies will
be assessed by visual inspection of the forest plot for overlapping
CI; using the Chi² test for homogeneity with a significance level of
α (alpha) = 0.1, and the I² statistic for quantifying inconsistency
(estimating the percentage of variation in effect estimates due to
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heterogeneity rather than sampling error), where I² values between
0% and 40% will be judged to indicate little heterogeneity, be-
tween 30% and 60% to indicate moderate heterogeneity, between
50% and 90% to indicate substantial heterogeneity, and between
75% and 100% to indicate considerable heterogeneity (Higgins
2011). We will abstain from conducting a meta-analysis if there
is a very high level of heterogeneity and the trials seem to address
different questions. If it is not possible to conduct a meta-analysis
we will provide a narrative description of the pooled prevalence
estimate.
Study characteristics that may be important to assess include the
following:
1. Number of confounders included in the models; and
2. Analysis technique used.
Assessment of reporting biases
Reporting bias and missing studies are a more complex issue for
non-randomised studies than for RCTs. Registration and publi-
cation of protocols for non-randomised studies is not as common
as for RCTs. We aim to include a wide range of studies by us-
ing a broad search strategy, and we will handle different forms of
reporting bias, especially publication bias and outcome reporting
bias, according to the recommendations of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will draw funnel plots (estimated differences in treatment effects
against their standard error) and perform Egger’s statistical test for
small-study effects (Egger 1997). We will not visually inspect the
funnel plot if there are less than 10 studies in the meta-analysis, as
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).Asymmetry could be due to publica-
tion bias, but could also be due to genuine heterogeneity between
small and large trials (Higgins 2011).
Data synthesis
We will include the following comparisons.
1. Comparative studies
• Case-control studies: intervention group compared to
placebo or no intervention.
• Cohort studies: intervention group compared to baseline
values of the intervention group.
2. Non-comparative studies
• We will only use case studies to identify less common (rare)
adverse events as defined according to the brand leader’s
Summary of Product Characteristics (SPC; Aagaard 2009).
• We will divide non-comparative cohort studies into
subgroups (for example, nervous system, digestive organ system),
and will report the different harms under each subgroup.
We are aware that some studies could have combined designs (for
example, cohort and case-control study design). We will assess
these separately. Furthermore, wewill include studies that compare
co-interventions, providing the compared intervention groups re-
ceive the same co-interventions.
Our analysis and conclusions of the results will differ between
comparative and non-comparative studies. We will use compara-
tive studies, such as case-control studies and comparative cohort
studies, to evaluate the RR of harms. For the comparative studies
we will perform a meta-analysis according to recommendations in
the latest version of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).We will also conduct ’Risk of bias’
assessments by usingACROBAT-NRSI (Sterne 2014).
Assuming clinical heterogeneity is not excessive (for example, there
is not too much variability in participants’ characteristics), we will
perform a meta-analysis of the results using the generic inverse
variance method. This method gives more weight to larger studies,
thus reducing imprecision in the pooled estimate of effect.We will
use the random-effects model in all meta-analyses and the fixed-
effectmodel in sensitivity analyses.We will present and analyse the
pooled estimates of the different adverse events according to study
design and study characteristics (for example, prospective study,
retrospective study and whether or not the study has a comparison
group).
Subgroup analysis and investigation of heterogeneity
When possible, we will conduct the following subgroup analyses.
1. Age (birth to 6 years, 7 to 11 years, and 12 to 18 years).
2. Sex (boys compared to girls).
3. Comorbidity (children with comorbid disorders compared
to children without comorbid disorders).
4. Subtype of ADHD (predominantly inattentive type versus
combined type).
Sensitivity analysis
We will assess the impact of heterogeneity on the overall pooled
effect estimate by removing studies (’outliers’) that are contribut-
ing to the heterogeneity. We will remove outliers one by one and
assess the impact on the overall outcome.
Wewill conduct sensitivity analyses to determine whether findings
are sensitive to the following:
1. Decisions made during the review process such as our
assessment of the level of clinical heterogeneity;
2. The impact of bias (studies with critical and serious risk of
bias);
3. Analytical technique used (for example, fixed-effect and
random-effects models);
4. Type of data collection (for example, different ways to
measure adverse events); and
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5. Imputed data (comparing the analyses with available
outcome data with those following the intention-to-treat (ITT)
principle).
’Summary of findings’ tables
We will construct a ’Summary of findings’ table for all outcomes,
using the software of the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) Working Group:
GRADEpro GDT 2015. We will assess the quality of the body
of evidence using the GRADE approach based on the extent to
which one can be confident that an estimate of effect or associ-
ation reflects the item being assessed. Considerations are due to:
within-trial risk of bias; the directness of the evidence; heterogene-
ity of the data; precision of effect estimates; and risk of publication
bias (Andrews 2013a; Andrews 2013b; Balshem 2011; Brunetti
2013;Guyatt 2011a;Guyatt 2011b;Guyatt 2011c;Guyatt 2011d;
Guyatt 2011e; Guyatt 2011f; Guyatt 2011g; Guyatt 2013a;
Guyatt 2013b; Guyatt 2013c; Mustafa 2013).
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A D D I T I O N A L T A B L E S
Table 1. Study design
Study design Description
Cohort study An observational study in which a defined group of
people (the cohort) is followed over time. The out-
comes of people in subsets of this cohort are compared,
to examine peoplewhowere exposed or not exposed (or
exposed at different levels) to a particular intervention
or other factor of interest. A prospective cohort study
assembles participants and follows them into the fu-
ture. A retrospective (or historical) cohort study iden-
tifies subjects from past records and follows them from
the time of those records to the present. Because sub-
jects are not allocated by the investigator to different
interventions or other exposures, adjusted analysis is
usually required tominimise the influence of other fac-
tors (confounders)
Case-control study A study that compares people with a specific disease
or outcome of interest (cases) to people from the same
population without that disease or outcome (controls)
, and which seeks to find associations between the out-
come and prior exposure to particular risk factors. This
design is particularly useful where the outcome is rare
and past exposure can be reliably measured. Case-con-
trol studies are usually retrospective, but not always
Taken from the Cochrane Glossary.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Search strategy
Ovid MEDLINE Efficacy
1. exp “attention deficit and disruptive behavior disorders”/
2. adhd.mp.
3. addh.mp.
4. adhs.mp.
5. (ad adj hd).mp.
6. ((attention* or behav*) adj3 (defic* or dysfunc* or disorder*)).mp.
7. ((disrupt* adj3 disorder*) or (disrupt* adj3 behav*) or (defian* adj3 disorder*) or (defian* adj3 behav*)).mp.
8. (impulsiv* or inattentiv* or inattention*).mp.
9. hyperactiv*.mp.
10. hyperkinesis*.mp.
11. exp Hyperkinesis/
12. (minimal adj brain adj3 disorder*).mp.
13. (minimal adj brain adj3 dysfunction*).mp.
14. (minimal adj brain adj3 damage*).mp.
15. or/1-14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomized controlled trials.mp.
19. random allocation.mp.
20. double blind method.mp.
21. single blind method.mp.
22. clinical trial.pt.
23. (clin* adj25 trial*).ti,ab.
24. ((singl* or doubl* or tripl* or trebl*) adj25 (blind* or mask* or dummy*)).mp.
25. exp Clinical Trial/
26. placebos.mp.
27. placebo*.ti,ab.
28. random*.ti,ab.
29. comparative study.mp.
30. Evaluation Studies as Topic/
31. exp Clinical Trials as Topic/
32. follow up studies.mp.
33. prospective studies.mp.
34. (control* or prospectiv* or volunteer*).ti,ab.
35. Epidemiologic studies/
36. Exp case control studies/
37. Exp cohort studies/
38. Case control.tw.
39. (cohort adj (study or studies)).tw.
40. Cohort analy$.tw.
41. (Follow up adj (study or studies)).tw.
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(Continued)
42. (observational adj (study or studies)).tw.
43. Longitudinal.tw.
44. Retrospective.tw.
45. Cross sectional.tw.
46. Cross-sectional studies
47. or/16-46
48. 15 and 47
49. Methylphenidate.mp. or Methylphenidate/
50. Aptensio.mp.
51. Attenta.mp.
52. Biphentin.mp.
53. Calocain.mp.
54. Centedrin*.mp.
55. Concerta.mp.
56. Daytrana.mp.
57. Dexmethylphenidat*.mp.
58. Difumenil.mp.
59. Elmifiten.mp.
60. Equasym.mp.
61. Focalin.mp.
62. Matoride.mp.
63. Medikid.mp.
64. Medikinet.mp.
65. Meridil.mp.
66. Metadate.mp.
67. Methyl phenidat*.mp.
68. Methyl phenidylacetat*.mp.
69. Methylfenid*.mp.
70. Methylin.mp.
71. Methylofenidan.mp.
72. Methylphenid*.mp.
73. Methyl phenidyl acetat*.mp.
74. Methypatch.mp.
75. Metidate.mp.
76. Metilfenidato.mp.
77. Motiron.mp.
78. MPH.mp.
79. Omozin.mp.
80. Penid.mp.
81. Phenidyl hydrochlorid*.mp.
82. Phenidylat*.mp.
83. Plimasin*.mp.
84. PMS-Methylphenid*.mp.
85. Quazym.mp/
86. Quilli*.mp.
87. Richter Works.mp.
88. Riphenidat*.mp.
89. Ritalin*.mp.
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(Continued)
90. Rubifen.mp.
91. Stimdat*.mp.
92. Tifinidat.mp.
93. Tranquilyn.mp.
94. Tsentedrin*.mp.
95. or/49-94
96. 48 and 95
97. exp Child/
98. exp Adolescent/
99. exp Infant/
100. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or
toddler* or school child* or youth*).mp.
101. or/97-100
102. 96 and 101
Adverse events
1. Methylphenidate.mp. or Methylphenidate/
2. Aptensio.mp.
3. Attenta.mp.
4. Biphentin.mp.
5. Calocain.mp.
6. Centedrin*.mp.
7. Concerta.mp.
8. Daytrana.mp.
9. Dexmethylphenidat*.mp.
10. Difumenil.mp.
11. Elmifiten.mp.
12. Equasym.mp.
13. Focalin.mp.
14. Matoride.mp.
15. Medikid.mp.
16. Medikinet.mp.
17. Meridil.mp.
18. Metadate.mp.
19. Methyl phenidat*.mp.
20. Methyl phenidylacetat*.mp.
21. Methylfenid*.mp.
22. Methylin.mp.
23. Methylofenidan.mp.
24. Methylphenid*.mp.
25. Methyl phenidyl acetat*.mp.
26. Methypatch.mp.
27. Metidate.mp.
28. Metilfenidato.mp.
29. Motiron.mp.
30. MPH.mp.
31. Omozin.mp.
32. Penid.mp.
33. Phenidyl hydrochlorid*.mp.
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(Continued)
34. Phenidylat*.mp.
35. Plimasin*.mp.
36. PMS-Methylphenid*.mp.
37. Quazym.mp.
38. Quilli*.mp.
39. Richter Works.mp.
40. Riphenidat*.mp.
41. Ritalin*.mp.
42. Rubifen.mp.
43. Stimdat*.mp.
44. Tifinidat.mp.
45. Tranquilyn.mp.
46. Tsentedrin*.mp.
47. or/1-46
48. (ae or co or de).fs.
49. (safe or safety or (side adj1 effect*) or (undesirable adj1 effect*) or (treatment adj1 emergent) or tolerability
or tolerance or tolerate or toxicity or toxic or adrs or adr or harm or harms or harmful or complication* or risk
or risks or (unintended adj1 event*) or (unintended adj1 effect*)).ti,ab.
50. (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
51. or/48-50
52. exp Child/
53. exp Adolescent/
54. exp Infant/
55. (child* or boy* or girl* or adolescen* or teen* or preschool or pre school or infant* or baby or babies or
toddler* or school child* or youth*).mp.
56. or/52-55
57. exp Mood Disorders/
58. (depression or depressive).ti,ab.
59. exp Psychotic Disorders/
60. (psychosis or (psychotic adj4 symptom*)).ti,ab.
61. exp Body Weight/ or Anorexia/
62. ((loss or lose or losing or reduc*) adj3 (weight or appetite)).ti,ab.
63. ((reduc* or retard* or inhibit* or deficit*) adj4 growth).ti,ab.
64. exp Hypertension/
65. Heart Rate/
66. exp tachycardia/
67. (increas* adj4 (heart rate or pulse or blood pressure)).ti,ab.
68. exp Death, Sudden/
69. death.ti,ab.
70. exp Infertility/
71. (((loss or reduc*) adj4 fertility) or infertility).ti,ab.
72. exp Carcinogens/
73. exp Neoplasms/
74. ((risk adj2 cancer) or (cytogenetic adj2 effect*)).ti,ab.
75. or/57-74
76. 51 or 75
77. 47 and 56 and 76
78. Methylphenidate/ae, po, to
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79. 56 and 78
80. 77 or 79
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